← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pharmathene, Inc.
Annapolis, MD
$28,565,730
Total funding
4
Grants
Funding over time
peak $12M · FY2006–17$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$28,565,730 · 4
By mechanism
N01$27,301,977 · 3
U01$1,263,753 · 1
Investigators at Pharmathene, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of a Third Generation Anthrax Vaccine$10,000,000
N01 · FY2008 · AI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$5,206,725
N01 · FY2014 · AI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$4,028,420
N01 · FY2017 · AI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$3,818,071
N01 · FY2016 · AI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$2,250,652
N01 · FY2015 · AI
Development of a Human Monoclonal Antibody for Inhalational Anthrax$1,998,109
N01 · FY2008 · AI
Novel Therapeutic Agent to Treat Nerve Agent Exposure after Civilian Attack$422,381
U01 · FY2010 · NS
Novel Therapeutic Agent to Treat Nerve Agent Exposure after Civilian Attack$329,739
U01 · FY2006 · NS
Novel Therapeutic Agent to Treat Nerve Agent Exposure after Civilian Attack$261,816
U01 · FY2007 · NS
Novel Therapeutic Agent to Treat Nerve Agent Exposure after Civilian Attack$249,816
U01 · FY2009 · NS
Novel Therapeutic Agent to Treat Nerve Agent Exposure after Civilian Attack$1
U01 · FY2008 · NS